SEC Filings

Form 10-K
ROCKET PHARMACEUTICALS, INC. filed this Form 10-K on 03/08/2019
Document Outline
Entire Document (6061.8 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - Table of Contents
Page 3 - FORWARD-LOOKING STATEMENTS
Page 4 - PART I
Page 5 - Essential Terminology.
Page 6 - Fanconi Anemia Complementation Group A (FANCA):
Page 7 - Rationale for Gene Therapy in FA
Page 8 - Regulatory Status
Page 9 - Current Therapy
Page 10 - Current Therapy
Page 11 - Current Therapy
Page 12 - CRISPR/Cas9 gene editing in Fanconi Anemia:
Page 13 - Intellectual Property
Page 14 - Material Contracts
Page 15 - Contract Research and Collaboration Agreement with Lund University and J. Richter
Page 16 - License Agreement for LAD-I with CIEMAT and UCLB
Page 17 - Competition
Page 18 - Government Regulation
Page 19 - Disclosure of Clinical Trial Information
Page 20 - N/A
Page 21 - The Hatch-Waxman Amendments
Page 22 - Post-Marketing Requirements
Page 23 - Coverage and Reimbursement
Page 24 - N/A
Page 25 - Research and Development ( R D )
Page 26 - We may need to raise additional funding, which may not be available on acceptable terms, or at all.
Page 27 - We have never generated any revenue from product sales and may never be profitable.
Page 28 - We may encounter substantial delays in commencement, enrollment or completion of our clinical trials
Page 29 - We have not completed any clinical studies of our current product candidates. Initial or interim res
Page 30 - Even if we obtain regulatory approval for a product candidate, our products will remain subject to r
Page 31 - Risks Related to Manufacturing, Development and Commercialization of Our Product Candidates
Page 32 - Our ability to successfully develop and commercialize our product candidates will substantially depe
Page 33 - The success of our research and development activities, clinical testing and commercialization, upon
Page 34 - We may not be successful in finding strategic collaborators for continuing development of certain of
Page 35 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 36 - Our internal computer systems, or those of our third-party collaborators or other contractors, may f
Page 37 - Affordable Care Act and Other Reform Initiatives
Page 38 - European Union Drug Development
Page 39 - Healthcare legislative reform measures may have a material adverse effect on our business and result
Page 40 - Other Regulations
Page 41 - Risks Related to Our Intellectual Property
Page 42 - If we breach our license agreements, it could have a material adverse effect on our commercializatio
Page 43 - If we are unable to protect the confidentiality of our trade secrets, our business and competitive p
Page 44 - Third-party claims of intellectual property infringement may prevent or delay our development and co
Page 45 - We may not be successful in obtaining or maintaining necessary rights to gene therapy product compon
Page 46 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 47 - Issued patents covering our product candidates could be found invalid or unenforceable if challenged
Page 48 - Risks related to ownership of our common stock
Page 49 - RTW Investments, LP, our principal stockholder, may have the ability to significantly influence all
Page 50 - Laboratory Leases
Page 51 - Issuer Purchases of Equity Securities
Page 52 - Unless otherwise indicated, references to the terms the combined company, Rocket, the Company, we, o
Page 53 - in vivo
Page 54 - Financial Overview
Page 55 - Rocket General and Administrative Expenses
Page 56 - Research and Development Expenses
Page 57 - Liquidity and Capital Resources
Page 58 - Cash Flows
Page 59 - Off-Balance Sheet Arrangements
Page 60 - Impairment of Long-Lived Assets
Page 61 - Stock-Based Compensation
Page 62 - Evaluation of Disclosure Controls and Procedures
Page 63 - N/A
Page 64 - PART III. OTHER INFORMATION
Page 65 - PART IV
Page 66 - Exhibit Index
Page 67 - N/A
Page 68 - N/A
Page 69 - SIGNATURES
Page 70 - Rocket Pharmaceuticals, Inc.
Page 71 - Report of Independent Registered Public Accounting Firm
Page 72 - Rocket Pharmaceuticals, Inc.
Page 73 - Rocket Pharmaceuticals, Inc.
Page 74 - Rocket Pharmaceuticals, Inc.
Page 75 - Rocket Pharmaceuticals, Inc.
Page 76 - Rocket Pharmaceuticals, Inc.
Page 77 - Rocket Pharmaceuticals, Inc.
Page 78 - 3. Summary of Significant Accounting Policies
Page 79 - Investments
Page 80 - Property and Equipment
Page 81 - Foreign Currency Transactions
Page 82 - Net Loss Per Share
Page 83 - 4. Acquisition Accounting
Page 84 - 5. Fair Value of Financial Instruments
Page 85 - 7. Accounts Payable and Accrued Expenses
Page 86 - Derivatives and Hedging
Page 87 - 10. Share-Based Awards
Page 88 - 2004 Stock Option and Incentive Plan
Page 89 - Restricted Stock Units
Page 90 - Share-Based Compensation
Page 91 - Income Taxes
Page 92 - 13. Commitments and Contingencies
Page 93 - Securities Litigation
Page 94 - PKDpyruvate kinase deficiency Master Research Agreement with CIEMAT
Page 95 - 15. Strategic Research Collaboration
Page 96 - 18. Selected Quarterly Financial Data (unaudited)
Subdocument 2 - EX-10.19 - EXHIBIT 10.19
Page 1 - Exhibit 10.19
Page 2 - Accrued Amounts
Page 3 - Release
Page 4 - N/A
Page 5 - Net Benefit
Page 6 - Specified Employee Payment Date
Page 7 - ab initio
Page 8 - N/A
Subdocument 3 - EX-10.26 - EXHIBIT 10.26
Page 1 - Exhibit 10.26
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - ARTICLE 2
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - ARTICLE 3
Page 11 - i.e
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - Wall Street Journal
Page 16 - N/A
Page 17 - ARTICLE 5
Page 18 - ARTICLE 6
Page 19 - N/A
Page 20 - N/A
Page 21 - ARTICLE 7
Page 22 - ARTICLE 8
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - ARTICLE 9
Page 27 - ARTICLE 10
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Page 32 - N/A
Page 33 - Exhibit A-1
Page 34 - Exhibit A-2
Page 35 - Exhibit A-3
Page 36 - N/A
Page 37 - N/A
Page 38 - Exhibit B
Page 39 - About Danon Disease
Page 40 - REGENXBIO Forward-Looking Statements
Subdocument 4 - EX-21.1 - EXHIBIT 21.1
Page 1 - N/A
Subdocument 5 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 6 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 7 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 8 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer